Sign in
Taking peopleNo phase

The Asia-Pacific Mitral & Tricuspid Valve-in-Valve/Valve-in-Ring Registry

Key facts

Who runs it
Prince of Wales Hospital, Shatin, Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
15 people, planned
Started
29 Jun 2026
Expected to end
31 Dec 2035
Type of study
Observational, 2 groups
Record updated
18 September 2026

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (4)Hide the full registry criteria

Who can take part

  • Age ≥ 21
  • Had at least one documented Mitral valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Mitral valve-in-valve/valve-in-ring procedure. (Prospective) OR Had at least one documented Tricuspid valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Tricuspid valve-in-valve/valve-in-ring procedure. (Prospective)

Who cannot take part

  • Any other conditions which investigator deems unsuitable for participation
  • Active endocarditis

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Structural heart disease or mitral valve regurgitation

This trial is currently available in Hong Kong.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A significant number of patients with severe mitral and tricuspid valve disease have been previously treated with either valve repair with annuloplasty rings or valve replacement with bioprosthetic/mechanical valves. Over time, these bioprosthetic valves and rings may fail resulting in recurrence of the valvular disease. The technical aspects of a re-do operation are complex and these patients are often times at high risk for repeat open surgery. The emergence of transcatheter options may provide a safer and less invasive alternative to open surgery. Majority of the data currently exist for Western cohorts with limited longer-term outcomes. Data on this therapy is particularly lacking in the Asia-Pacific region, especially important in the light of known differences in body habitus and size.

The 2 groups in the trial

  • Prospective

    Patient planned to undergo a Mitral valve-in-valve/valve-in-ring procedure.

  • Retrospective

    Patient that had at least one documented Mitral valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07296016, who can take part
Record updated
18 September 2026